Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)

Digestive Diseases and Sciences

Volumn 58, Issue 10, 2013, Pages 3017-3023

  Stepanova, Maria ^a,d   Rafiq, Nila ^a   Makhlouf, Hala ^b   Agrawal, Ritambhara ^a   Kaur, Ishmeet ^a   Younoszai, Zahra ^a   McCullough, Arthur ^c   Goodman, Zachary ^a,d   Younossi, Zobair M ^a,d  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

Follow up study; Mortality; Non alcoholic fatty liver disease (NAFLD); Non alcoholic steatohepatitis (NASH)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; SEX RATIO;

ADULT; AGE FACTORS; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; SURVIVAL RATE;

EID: 84885304313     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2743-5     Document Type: Article

References (38)

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
2. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792-798.
3. Ong JP, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:1-16.
4. Rafiq N, Younossi ZM. Effects of weight loss on non-alcoholic fatty liver disease. Semin Liver Dis. 2008;28:427-433.
5. Younossi Z, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988-2008. Clin Gastroenterol Hepatol. 2011;9:524-530.
6. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023.
7. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310-315.
8. Gholam PM, Flanebaum L, Machan JT. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399-408.
9. Beymer C, Kowdley KV, Larson AA. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138:1240-1244.
10. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413-1419.
11. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for non-alcoholic steatohepatitis (NASH): inter-protocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874-1882.
12. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-1719.
13. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-138.
14. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873.
15. Rafiq N, Bai C, Fang Y, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234-238.
16. Soderberg C, Stal P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology. 2010;51:595-602.
17. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-49. doi: 10.3109/07853890.2010.518623.
18. Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266.
19. Ong J, Pitts A, Younossi ZM. Increased mortality and liver-related mortality in patients with nonalcoholic fatty liver disease. J Hepatol. 2008;49:608-612.
20. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut. 2010;59:1410-1415.
21. Dunn W, Xu R, Wingard DL, et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263-2271.
22. World Health Organization. ICD 10: International Statistical Classification of Diseases and Related Health Problems. Arlington, VA: American Psychiatric Publishing, Inc.; 1992.
23. Larter CZ, Chitturi S, Heydet D, Farrell GC. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25:672-690.
24. Cusi K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis. Clin Liver Dis. 2009;13:545-563.
25. Gentile CL, Pagliassotti MJ. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease. J Nutr Biochem. 2008;19:567-576.
26. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of non alcoholic steatohepatitis and fibrosis in patients with non alcoholic fatty liver disease and low visceral adiposity. J Hepatol. 2011;54:1244-1249. doi: 10.1016/j.jhep.2010.09.037.
27. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol. 2011;46:63-69.
28. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease (NAFLD), metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism. 2013;62:352-360. doi: 10.1016/j.metabol.2012.08.005.
29. Younossi ZM, Gramlich T, Matteoni C, Boparai N, McCullough A. Non-alcoholic fatty liver disease in patients with type II diabetes. Clin Gastroenterol Hepatol. 2004;2:262-265.
30. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191:235-240.
31. Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947-1953.
32. Targher G, Day CP. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. Hepatology. 2011;53:375. doi: 10.1002/hep.23901.
33. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012;10:646-650.
34. Xu J, Kochanek KD, Murphy SL, Tejada-Vera B. Deaths: final data for 2007. Natl Vital Stat Rep. 2010;58:1-136.
35. Lam B, Younossi ZM. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2010;3:121-137.
36. Younossi ZM, Venkatesan C. A 2012 clinical update for internists in adult nonalcoholic fatty liver disease. Panminerva Med. 2012;54:29-37. Review.
37. Venkatesan C, Younossi ZM. Potential mechanisms underlying the associations between liver enzymes and risk for type 2 diabetes. Hepatology. 2012;55:968-970.
38. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-530.e1; quiz e60.